Zhaopei Liu

13PUBLICATIONS
16CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer cell biologyGene and molecular therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 11, 2026
TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.

|Jun 29, 2026
Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.

|May 20, 2026
Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.

|May 15, 2026
Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.

|Dec 10, 2025
Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma.

Lingkai Zhang, Zhaopei Liu, Yawei Ding

|Sep 26, 2025
Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study.

Zhaopei Liu, Kaifeng Jin, Ziyue Xu

Pageof 3

Frequent Collaborators

12 joint publications

Kaifeng Jin

11 joint publications

Jiejie Xu

11 joint publications

Han Zeng

10 joint publications

Zewei Wang